Thoratec Corp. (Nasdaq: THOR) disappointed with lower second quarter revenue and earnings of 30 cents per diluted share compared with 40 cents per diluted share a year earlier prompting downgrades. Shares of the medical device maker plummeted $9.50 to $23.07.
Thoratec disappoints
August 07, 2014 at 13:37 PM EDT